Printer Friendly

UNIQUE NEW NASAL SPRAY FORM OF STADOL(R) ENTERS PRESCRIPTION PAIN RELIEF MARKET

 UNIQUE NEW NASAL SPRAY FORM OF STADOL(R)
 ENTERS PRESCRIPTION PAIN RELIEF MARKET
 PRINCETON, N.J., Aug. 13 /PRNewswire/ -- An easy-to-administer nasal spray dosage of a proven analgesic was introduced recently by Mead Johnson Laboratories, a division of Bristol-Myers Squibb Company. The only analgesic available as a nasal spray, Stadol(R) NS(TM) (butorphanol tartrate) has been shown to be effective for treating post-surgical pain and migraine headache pain.
 Butorphanol tartrate has a 14-year record of safety and efficacy as an injectable analgesic marketed under the trademark Stadol(R). Indicated for the management of pain when the use of an opioid analgesic is appropriate, the new nasal spray delivery form of Stadol is not a federally controlled pain reliever.
 The new nasal delivery of butorphanol tartrate combines rapid pain relief with the convenience of enabling patients to self-administer. In addition, the nasal spray form enables physicians to initiate therapy with a lower dose and increase the dose if needed.
 Clinical trials using Stadol NS were conducted in patients following invasive surgical procedures such as general abdominal surgery, hysterectomy and caesarean section. Stadol NS also was studied in migraine headache sufferers.
 Wayne Schwesinger, M.D., a Stadol NS investigator and surgeon who is Professor of Surgery, University of Texas Health Science Center at San Antonio, said he would use Stadol NS for post-surgical pain relief in women following general abdominal surgery, hysterectomy, caesarean section and cholecystectomy.
 "We found transnasal butorphanol tartrate to be as effective as the injectable version of the drug for pain relief and excellent for general post-surgical use, especially in patients recovering at home," he noted.
 Schwesinger, who compared Stadol NS with intramuscular meperidine in a clinical trial involving 137 patients, noted that the transnasal product "provided comparable pain relief to meperidine without the discomfort and inconvenience of an injectable drug and was less traumatic for our patients."
 Seymour Diamond, M.D., another Stadol NS investigator who is executive director of the Chicago-based National Headache Foundation, said migraine headache patients in particular may benefit from the sedative and pain-relieving effects of Stadol NS.
 "There's no question that Stadol NS will fill a void in the treatment of migraine headaches that 'break through' -- that is, migraines that aren't prevented by abortive or prophylactic medicine," said Diamond, who also serves as director of the nationally known Diamond Headache Center, also in Chicago. "Until now, butorphanol tartrate was available only in an injectable form. Now that it is available in a nasal form, patients will be able to take it without having to go to their physicians or to an emergency room.
 "Rapid pain relief combined with convenience -- in a drug with a low abuse potential -- is especially important to migraine patients because the headaches are so debilitating," Diamond explained. "Because of the disability and discomfort of migraine, the physician will now be able to use Stadol NS to relieve the patient's migraine pain in the home environment."
 Stadol NS should always be used at the recommendation of a physician. Because of the agent's possible effects of dizziness and sedation, patients are cautioned not to drive or operate heavy machinery while using the drug.
 Stadol NS is supplied in a child-resistant prescription vial containing a metered-dose spray pump and 2.5 ml bottle of solution. On average, each bottle will deliver three to four days of therapy.
 In addition to Stadol NS, Mead Johnson Laboratories products include Estrace(R), for estrogen replacement therapy; Ovcon(R), an oral contraceptive; Vagistat-1(R), a vaginal antifungal treatment; and Natalins(R) Rx, a prenatal vitamin.
 Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non-prescription medicines.
 -0- 8/13/92
 /CONTACT: Patrick Donohue of Bristol-Myers Squibb, 609-252-5685, or Christie McCoy of Ted Klein & Company, 212-477-9007, for Bristol-Myers/
 (BMY) CO: Bristol Myers Squibb Company ST: New Jersey IN: MTC SU: PDT


LR-OS -- NY046 -- 9690 08/13/92 13:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 13, 1992
Words:676
Previous Article:SERVICE CORPORATION INTERNATIONAL DECLARES SECOND QUARTER DIVIDEND
Next Article:WAL-MART STORES DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
FDA APPROVES BRISTOL-MYERS SQUIBB'S STADOL NS NEW PRESCRIPTION NASAL SPRAY ANALGESIC
BUTORPHANOL TARTRATE NASAL SPRAY OFFERS CONVENIENT THERAPY FOR TREATING MIGRAINE PAIN
BRISTOL-MYERS SQUIBB AND CEPHALON TO COPROMOTE STADOL NS; PAIN MANAGEMENT THERAPY IS FIRST PRODUCT REVENUE OPPORTUNITY FOR CEPHALON
NEW TREATMENT CHOICE OFFERS HOPE FOR WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
ATROVENT NASAL SPRAY IS THE FIRST MEDICATION IN A NEW CLASS OF NASAL SPRAYS TO RELIEVE A RUNNY NOSE
ASTELIN (azelastine HCI) Nasal Spray, 137 mcg, Now Available For Seasonal Allergic Rhinitis
First Commercial Quantities of Nascobal(TM) Manufactured and Shipped for October Launch
Imitrex(R) Nasal Spray Now Available for People With Migraine in the U.S.
Novartis Pharmaceuticals Corporation Receives FDA Clearance to Market Migranal(R) (dihydroergotamine mesylate, USP) Nasal Spray
Migranal(R) Nasal Spray Now Available to Treat Migraine Headaches

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters